Abstract
Diabetic peripheral neuropathy (DPN) is the most common diabetic complication and is the leading cause of diabetes-related hospital admissions and non-traumatic amputations. DPN is also associated with a poor quality of life and high economic costs for both type 1 and type 2 diabetic patients. An effective treatment for DPN, besides tight glycemic control, is not yet available. The pathogenesis of DPN is complex and involves an intertwined array of mechanisms. Glucose- mediated alteration of cyclooxygenase (COX) pathway activity with subsequent impaired production and function of prostaglandins (PGs) is one mechanism that is implicated in the pathogenesis of DPN. COX-2, the inducible COX isoform, is upregulated in a variety of pathophysiological conditions including diabetes. COX-2 upregulation has tissuespecific consequences and is associated with activation of downstream inflammatory reactions. We have previously reported that COX-2 is upregulated in the peripheral nerves and dorsal root ganglia neurons in experimental diabetes and that COX-2 gene inactivation and/or selective COX-2 inhibition provides protection against various DPN deficits. This review will summarize current evidence supporting the role of COX-2 activation in inducing diabetic neurovascular dysfunction and that modulation of the COX-2 pathway is a potential therapeutic target for DPN.
Keywords: Cyclooxygenase-2, diabetes, diabetic peripheral neuropathy, oxidative stress, prostaglandins, inflammation
Current Drug Targets
Title: Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy
Volume: 9 Issue: 1
Author(s): Rodica Pop-Busui, Aaron P. Kellogg and Hsinlin Thomas Cheng
Affiliation:
Keywords: Cyclooxygenase-2, diabetes, diabetic peripheral neuropathy, oxidative stress, prostaglandins, inflammation
Abstract: Diabetic peripheral neuropathy (DPN) is the most common diabetic complication and is the leading cause of diabetes-related hospital admissions and non-traumatic amputations. DPN is also associated with a poor quality of life and high economic costs for both type 1 and type 2 diabetic patients. An effective treatment for DPN, besides tight glycemic control, is not yet available. The pathogenesis of DPN is complex and involves an intertwined array of mechanisms. Glucose- mediated alteration of cyclooxygenase (COX) pathway activity with subsequent impaired production and function of prostaglandins (PGs) is one mechanism that is implicated in the pathogenesis of DPN. COX-2, the inducible COX isoform, is upregulated in a variety of pathophysiological conditions including diabetes. COX-2 upregulation has tissuespecific consequences and is associated with activation of downstream inflammatory reactions. We have previously reported that COX-2 is upregulated in the peripheral nerves and dorsal root ganglia neurons in experimental diabetes and that COX-2 gene inactivation and/or selective COX-2 inhibition provides protection against various DPN deficits. This review will summarize current evidence supporting the role of COX-2 activation in inducing diabetic neurovascular dysfunction and that modulation of the COX-2 pathway is a potential therapeutic target for DPN.
Export Options
About this article
Cite this article as:
Pop-Busui Rodica, Kellogg P. Aaron and Cheng Thomas Hsinlin, Cyclooxygenase-2 Pathway as a Potential Therapeutic Target in Diabetic Peripheral Neuropathy, Current Drug Targets 2008; 9 (1) . https://dx.doi.org/10.2174/138945008783431691
DOI https://dx.doi.org/10.2174/138945008783431691 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Molecular Mechanisms and Therapeutic Application of NSAIDs and Derived Compounds in Alzheimers Disease
Current Alzheimer Research Apo-E4 Allele in Conjunction with Aβ42 and Tau in CSF: Biomarker for Alzheimers Disease
Current Alzheimer Research Minocycline Repurposing in Critical Illness: Focus on Stroke
Current Topics in Medicinal Chemistry Curcumin Exposure Modulates Multiple Pro-Apoptotic and Anti-Apoptotic Signaling Pathways to Antagonize Acetaminophen-Induced Toxicity
Current Neurovascular Research Driving Cellular Plasticity and Survival Through the Signal Transduction Pathways of Metabotropic Glutamate Receptors
Current Neurovascular Research Herbal Medicines and Nutraceuticals for Diabetic Vascular Complications: Mechanisms of Action and Bioactive Phytochemicals
Current Pharmaceutical Design Current Pharmaceutical Interventions and Drug Design in the Management of Diabetes and Diabetic Complications
Current Pharmaceutical Design Copper Status Abnormalities and How to Measure Them in Neurodegenerative Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Nano-medicine Improving the Bioavailability of Small Molecules for the Prevention of Neurodegenerative Diseases
Current Pharmaceutical Design DNA Methylation and MicroRNA-Based Biomarkers for Risk of Type 2 Diabetes
Current Diabetes Reviews Under the Microscope: Focus on Chlamydia pneumoniae Infection and Multiple Sclerosis
Current Neurovascular Research Huntingtons Disease: The Value of Transcranial Meganetic Stimulation
Current Medicinal Chemistry Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis
Current Neuropharmacology Commentary: Stephen William Hawking (8 January 1942 – 14 March 2018)
CNS & Neurological Disorders - Drug Targets Metabolism and Pharmacological Mechanisms of Active Ingredients in <i>Erigeron breviscapus</i>
Current Drug Metabolism Interindividual Variability in the Efficacy of Oral Antiplatelet Drugs: Definitions, Mechanisms and Clinical Importance
Current Pharmaceutical Design Synthesis, ADME Evaluation, and In Vitro Antimycobacterial Studies of a Novel Series of 2-Thiazolylimino-5-Arylidene-4-Thiazolidinone Derivatives
Anti-Infective Agents Type 2 Diabetes Mellitus and the Elderly: An Update on Drugs Used to Treat Glycaemia
Current Vascular Pharmacology Dietary Antioxidants and Oxidative Stress from a Human and Plant Perspective: A Review
Current Nutrition & Food Science Neurotrophic Factors for the Investigation and Treatment of Movement Disorders
Current Medicinal Chemistry - Central Nervous System Agents